2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Sezary Syndrome
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Hodgkin Disease
1
Carcinoma, Hepatocellular
1
Interventions
Cyclophosphamide
45
Peripheral Blood Stem Cell Transplantation
43
fludarabine phosphate
42
Mycophenolic Acid
30
Whole-Body Irradiation
27
Cyclosporine
27
Busulfan
26
Tacrolimus
23
Antilymphocyte Serum
23
Methotrexate
20
Etoposide
20
romidepsin
19
Filgrastim
19
Melphalan
16
Radiotherapy
15
Flow Cytometry
15
Vorinostat
13
Methylprednisolone
13
Brentuximab Vedotin
13
Lenalidomide
12
Bexarotene
12
mogamulizumab
11
Psychiatric Rehabilitation
11
Bortezomib
11
Therapeutics
10
Rituximab
10
Gemcitabine
10
fludarabine
9
Polymerase Chain Reaction
9
Biopsy
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, T-Cell, Cutaneous
×
resminostat
×
Clear all
NCT02953301
2024-08-30
RESMAIN
4SC AG
Phase 2
Completed
201 enrolled